VanEck vs. Invesco — Which Pharmaceutical ETF Delivers More?
By John Nada·Jul 4, 2026·5 min read
VanEck offers cost-efficiency and higher income potential, while Invesco shines with recent price gains. Which ETF suits your strategy?
In the battle for pharmaceutical ETF dominance, VanEck Pharmaceutical ETF and Invesco Pharmaceuticals ETF each bring distinct advantages to the investor table. But which one really delivers more bang for your buck?
VanEck offers investors a cost-efficient entry at a 0.36% expense ratio, outshining Invesco by saving 0.21 percentage points on fees. According to Yahoo Finance, this makes VanEck the more attractive option for those prioritizing cost. The lower expense ratio can significantly impact long-term investments by reducing the overall cost burden, allowing more capital to be invested in the core holdings.
However, VanEck isn’t just about saving you pennies; it’s also about making them. With a higher dividend yield of 2.00%, driven by significant stakes in giants like Eli Lilly & Co, VanEck suits income-seeking portfolios perfectly. This higher yield reflects the fund's focus on stable, mature pharmaceutical companies known for generating consistent cash flows, which are essential for paying dividends.
The VanEck Pharmaceutical ETF focuses exclusively on the healthcare sector with 26 holdings, seeking to replicate the MVIS US Listed Pharmaceutical 25 Index. Its largest positions include Eli Lilly & Co at 20.24%, Novartis at 10.63%, and Merck & Co at 9.85%. It was launched in 2011, and since then, it has aimed to provide investors with a clear and concentrated exposure to leading pharmaceutical companies. The focus on fewer holdings compared to its peers allows VanEck to potentially leverage the performance of its top investments more effectively, though this also introduces sector-specific risks.
Invesco doesn’t stand idly by. Its 0.90% dividend yield pales in comparison, but recent price momentum suggests a different kind of appeal. For those chasing sector momentum, its capital spread across 29 holdings—including Abbott Laboratories and AbbVie—has proven effective. This broader distribution of investments may provide a buffer against the volatility of individual stock performance, making Invesco potentially more appealing to risk-averse investors.
The Invesco Pharmaceuticals ETF spreads its capital across 29 holdings through a non-diversified approach. Its largest positions include Eli Lilly & Co at 5.22%, Abbott Laboratories at 5.16%, and AbbVie at 5.14%. It was launched in 2005, giving it a longer track record for investors to analyze its historical performance. Invesco’s strategy of maintaining 100% healthcare exposure but with a wider array of investments could appeal to those who value diversification within a single sector.
One key consideration for investors is the volatility these ETFs face relative to the broader market. Beta, a measure of price volatility relative to the S&P 500, can provide insight into how much risk an ETF might introduce into a portfolio. While the source text does not provide specific beta values, understanding this metric is crucial for investors looking to assess the risk associated with their investments in these pharmaceutical ETFs.
Gold May Dip Further—Jim Cramer's Take on Agnico Eagle
Jim Cramer warns of potential gold price dip, despite liking Agnico Eagle.
The healthcare sector, and pharmaceuticals in particular, is known for its volatility due to the high-risk, high-reward nature of drug development. Regulatory approvals, patent expirations, and competitive pressures can all lead to significant swings in stock prices. For VanEck, which focuses on fewer companies, these factors can have a more pronounced impact on its performance compared to Invesco’s more diversified approach.
For those focused on income, VanEck's higher dividend yield is particularly appealing. The ETF has paid $2.15 per share over the trailing 12 months, which on its recent ~$109.35 share price works out to a 2.00% yield. This yield is especially attractive in a low-interest-rate environment, where fixed income investments may offer limited returns.
In contrast, Invesco Pharmaceuticals ETF has paid $1.06 per share over the trailing 12 months, which on its recent ~$118.45 share price works out to a 0.90% yield. While this yield is lower, the potential for capital appreciation through price momentum may compensate for the reduced income, especially for investors with a higher risk tolerance.
The real choice boils down to priorities. Are you in it for the cost savings and income, or do you want to ride the momentum wave? The decision isn’t straightforward, and it’s investors who need to weigh these factors carefully. How will these ETFs respond to shifting pharmaceutical landscapes?
Understanding the underlying holdings and the strategic focus of each ETF is critical for making an informed decision. VanEck’s concentrated approach on larger pharmaceutical companies may offer more stability and income, but also comes with higher exposure to sector-specific risks. Invesco’s broader diversification within the healthcare sector might appeal to those looking for potential growth through capital appreciation while maintaining some degree of risk mitigation.
Investors should also consider their own financial goals, risk tolerance, and investment horizon when choosing between these two ETFs. Those seeking stable income and cost-efficiency might lean towards VanEck, while those willing to embrace more risk for potential growth might find Invesco more aligned with their objectives.
Ultimately, the choice between VanEck and Invesco is a personal one, depending on what each investor values most in their portfolio. The decision may also be influenced by external factors such as changes in healthcare policy, technological advancements in pharmaceuticals, and global market conditions, all of which can impact the performance of these ETFs.